6585. Soothene ointment. (F.D.C. No. 45480. S. No. 16–346 R.)

QUANTITY: 11 cases, 144 ctnd. tubes each, at Cincinnati, Ohio.

SHIPPED: 11–23–60, from St. Louis, Mo., by Neal Pharmacal Co. (St. Louis Magnesia Co.).

LABEL IN PART: (Tube and ctn.) "Soothene Contents 1 Oz. A Stainless Ointment * * * Active Ingredients: Carbolic Acid 3%; Zinc Oxide and Menthol in a specially formulated, soothing base. * * * Prepared for Soothene Medicine Co. Cincinnati, Ohio."

LIBELED: 2–16–61, S. Dist. Ohio.

CHARGE: 503(b)(4)—when shipped, the article was a drug subject to 503(b)(1) and its label failed to bear the statement "Caution: Federal law prohibits dispensing without prescription."

DISPOSITION: 3–22–61. Default—destruction.

6586. Reserpine tablets, dextro-amphetamine sulfate tablets, and Dexabarbital tablets. (F.D.C. No. 45324. S. Nos. 45–621/4 R, 45–627 R, 45–631 R.)

QUANTITY: 2 unlabeled jars containing a total of approximately 1,150 tablets of reserpine, purporting to be Serpasil, but being counterfeits thereof with "Ciba" embossed on one side of each tablet and the letter "S" scratched on the jar lids; 1 unlabeled tin containing approximately 2,900 orange-colored heart-shaped single-scored tablets of dextro-amphetamine sulfate, purporting to be Dexedrine Sulfate tablets, but being counterfeits thereof; 4 btls. containing a total of approximately 3,400 orange-colored heart-shaped single-scored tablets labeled in part "Dextro-Amphetamine Sulfate"; and 8 btls. containing a total of approximately 7,900 small green heart-shaped single-scored tablets labeled in part "Dexabarbital," at Aberdeen, N.C., in possession of Craig Drug Co.

SHIPPED: 12–6–60, by William L. "Tex" Palmer, or his son, William Palmer, of Palmer & Co., Houston, Tex.

LIBELED: 1–4–61, M. Dist. N.C.; amended libel 1–20–61.

CHARGE: Tablets purporting to be Serpasil tablets and Dexedrine Sulfate tablets, 502(b)—while held for sale, the tablets failed to bear a label containing (1) the name and place of business of the manufacturer, packer, or distributor, and (2) an accurate statement of the quantity of the contents; 502(e)(1)—the labels of the tablets failed to bear the common or usual name of the drugs; 502(f)—the labeling of the tablets failed to bear (1) adequate directions for use and (2) adequate warnings against use; 502(i)(2)—the tablets were imitations of other drugs; and 503(b)(4)—the labels of the tablets failed to bear the statement "Caution: Federal law prohibits dispensing without prescription."

Tablets labeled in part "Dextro-Amphetamine Sulfate." 502(b)(1)—while held for sale, the tablets failed to bear a label containing the name and place of business of the manufacturer, packer, or distributor; and 502(i)(2)—the tablets were an imitation of another drug.

Tablets labeled in part "Dexabarbital," 502(b)(1)—while held for sale, the tablets failed to bear a label containing the name and place of business of the manufacturer, packer, or distributor.

DISPOSITION: 2–15–61. Default—delivered to the Food and Drug Administration.